Corbus Pharmaceuticals Holdings Inc CRBP

NAS: CRBP | ISIN: US21833P1030 30/04/2025

7,470 USD (+3,75%)

(+3,75%) 30/04/2025

Grafiek Corbus Pharmaceuticals Holdings Inc

Grafiek Corbus Pharmaceuticals Holdings Inc

1 dag1d 3,75%
1 week1w -10,54%
1 maand1m 48,51%
3 maanden3m -21,45%
6 maanden6m -55,85%
1 jaar1j -79,95%
5 jaar5j 24,09%

Corbus Pharmaceuticals Holdings Inc in het nieuws

Toon enkel gratis nieuws

27 september 2023 · Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting · Persbericht

19 september 2023 · Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics · Persbericht

8 augustus 2023 · Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

31 juli 2023 · Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference · Persbericht

26 juni 2023 · Corbus Pharmaceuticals Set to Join Russell Microcap® Index · Persbericht

31 mei 2023 · Corbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference · Persbericht

9 mei 2023 · Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

1 mei 2023 · Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 avβ8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting · Persbericht

18 april 2023 · Corbus Pharmaceuticals Hosting Virtual 'Meet the Expert' Series: Blocking TGFβ with CRB-601--a New Play for an Old Target · Persbericht

17 april 2023 · Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting · Persbericht

Profiel Corbus Pharmaceuticals Holdings Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.corbuspharma.com

Hoofdzetel: Norwood, Massachusetts Verenigde Staten

CEO: Yuval Cohen

Werknemers: 52

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe